DARE — Dare Bioscience Income Statement
0.000.00%
Last trade - 00:00- $26.42m
- $10.72m
- $0.01m
- 14
- 34
- 57
- 27
Annual income statement for Dare Bioscience, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 10 | 2.81 | 0.01 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 27.4 | 38.7 | 41.4 | 33.7 | 3.08 |
| Operating Profit | -27.4 | -38.7 | -31.4 | -30.9 | -3.07 |
| Gain / Loss on Sale of Assets | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -27.4 | -38.7 | -30.9 | -30.2 | -4.05 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -27.4 | -38.7 | -30.9 | -30.2 | -4.05 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -27.4 | -38.7 | -30.9 | -30.2 | -4.05 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -27.4 | -38.7 | -30.9 | -30.2 | -4.05 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -10.9 | -7.67 | -4.39 | -4.15 | -2.8 |